Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionClaro Advisors LLC
Latest Disclosed Ownership568 shares
Latest Disclosed Value $ 438,881
Claro Advisors LLC reports 1.97% increase in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On April 21, 2026 - Claro Advisors LLC filed a 13F-HR form disclosing ownership of 568 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $438,881 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 557 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of 1.97% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-21 2026-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 568 11 1.97 439 2.10 0.0529
2026-02-17 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 557 102 22.42 430 67.58 0.0585
2025-11-12 2025-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 455 455 256 0.0373
2025-08-05 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 0 -620 -100.00 0 -100.00
2025-05-12 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 620 217 53.85 393 36.93 0.0527
2025-01-13 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 403 -75 -15.69 287 -42.83 0.0388
2024-11-07 2024-09-30 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 478 251 110.57 502 110.92 0.0649
2024-10-17 2024-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 1,358 1,131 263 0.0340
2024-07-31 2024-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 227 227 239 0.0372
2019-05-09 2019-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 0 -2 -100.00 0 -100.00
2019-02-14 2018-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 2 2 1 0.0008
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.